JPMorgan Chase analysts wrote in a note that the performance update from medical device company Convatec Group is expected to dispel market concerns regarding its ability to achieve its 2026 financial guidance. Previously, the market worried that Convatec would need to accelerate growth significantly in the second half of the year to meet its 2026 forecasts. However, with just six weeks left in the full year, the company has raised its revenue growth outlook and reaffirmed its margin guidance, which should put those concerns to rest. The company's stock is currently up 8.3%.